[Research on cyclin-dependent kinase inhibitors: state of the art and perspective].
Zuo
Ming-xin
MX
zlpharm@yahoo.com.cn
Chen
Xiao-guang
XG
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002453:Cell Cycle / Q000187:drug effects / Q000502:physiology*; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D016213:Cyclins / Q000378:metabolism*; D005419:Flavonoids / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D010880:Piperidines / Q000494:pharmacology / Q000627:therapeutic use; D011687:Purines / Q000494:pharmacology / Q000627:therapeutic use; D000077546:Roscovitine; D019311:Staurosporine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D016213:Cyclins; D005419:Flavonoids; D010880:Piperidines; D011687:Purines; D000077546:Roscovitine; C077990:alvocidib; C054852:7-hydroxystaurosporine; D018844:Cyclin-Dependent Kinases; D019311:Staurosporine